Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00436696 · ClinicalTrials.gov registry record
Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions
A clinical trial of Recurrent Neuroblastoma and Localized Resectable Neuroblastoma, sponsored by Children's Oncology Group.
- Completed
- Registry status
- 9,350
- Enrollment target
- 2
- Study locations
NCT00436696: Completed study of Recurrent Neuroblastoma and Localized Resectable Neuroblastoma, sponsored by Children's Oncology Group.
NCT00436696 is a study of Recurrent Neuroblastoma and Localized Resectable Neuroblastoma that has completed, run by Children's Oncology Group. The registered enrollment target is 9,350 participants, above the 101-participant average among 9 other Recurrent Neuroblastoma trials with a reported enrollment target (9157% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00436696, a study of Recurrent Neuroblastoma and Localized Resectable Neuroblastoma, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- 9,350 participants
- Enrollment target
- 2
- Study locations
Study Summary
This laboratory study is looking at genes in participants with neuroblastoma or noncancerous conditions. Identifying genes related to cancer may help in the study of cancer. It may also help doctors predict who is at risk of developing neuroblastoma.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
Study Locations (2)
Mississippi
- University of Mississippi Medical Center - Jackson
Pennsylvania
- Childrens Oncology Group - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,350 participants |
| Start Date | 2006-12-11 |
What the finished NCT00436696 record still lists
NCT00436696 is an observational study that tracks outcomes without assigning an intervention. Its 9,350 participants enrollment target places it among the larger protocols in the corpus, above the 101-participant average among 9 other Recurrent Neuroblastoma trials with a reported enrollment target (9157% higher).
The record links to 5 conditions, with Recurrent Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which Laboratory Biomarker Analysis is the first listed.
NCT00436696 reports a single indexed study location in Mississippi, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00436696 about?
NCT00436696 is a clinical study titled "Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions". This laboratory study is looking at genes in participants with neuroblastoma or noncancerous conditions. Identifying genes related to cancer may help in the study of cancer. It may also help doctors predict who is at risk of developing neuroblastoma.
What is the current status of trial NCT00436696?
This trial is currently completed. The enrollment target is 9,350 participants. The study started on 2006-12-11.
What conditions does trial NCT00436696 study?
This clinical trial studies the following conditions: Recurrent Neuroblastoma, Localized Resectable Neuroblastoma, Stage 4 Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma.
What interventions are being tested in trial NCT00436696?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT00436696?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00436696 being conducted?
This trial has 2 study locations across Mississippi, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00436696's enrollment target sits among peer trials
9,350 1st of 9 higher than 9 of 9 other Recurrent Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
RECRUITING · Phase 1
-
Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma
ACTIVE NOT RECRUITING
-
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
ACTIVE NOT RECRUITING · Phase 1
-
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
ACTIVE NOT RECRUITING · Phase 2
-
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06284408 · 9,460 participants · NA
Centralized Screening Unit (CSU) at Montefiore-Einstein
- NCT05080673 · 9,500 participants · NA
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
- NCT06946355 · 9,119 participants · NA
Food-based Support for Hospitalized Children and Their Families
- NCT02000089 · 9,000 participants · Phase 3
The Cancer of the Pancreas Screening-5 CAPS5)Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI